Type your tag names separated by a space and hit enter

    Ferrous sulfate reduces thyroxine efficacy in patients with hypothyroidism.

    Abstract

    OBJECTIVE

    To determine whether simultaneous ingestion of ferrous sulfate and thyroxine reduces the efficacy of thyroid hormone in patients with primary hypothyroidism.

    DESIGN

    Uncontrolled clinical trial.

    SETTING

    Outpatient research clinic of a tertiary care center.

    PATIENTS

    Fourteen patients with established primary hypothyroidism on stable thyroxine replacement.

    INTERVENTION

    All patients were instructed to ingest simultaneously, a 300-mg ferrous sulfate tablet and their usual thyroxine dose every day for 12 weeks.

    RESULTS

    After 12 weeks of ferrous sulfate ingestion with thyroxine, the mean level of serum thyrotropin (thyroid stimulating hormone, TSH) rose from 1.6 +/- 0.4 to 5.4 +/- 2.8 mU/L (P < 0.01), but the free thyroxine index did not change significantly. Subjective evaluation using a clinical score showed that nine patients had an increase in symptoms and signs of hypothyroidism; the mean score for the 14 patients changed from 0 to 1.3 +/- 0.4 (P = 0.011). When iron and thyroxine were mixed together in vitro, a poorly soluble purple complex appeared that indicated the binding of iron to thyroxine.

    CONCLUSIONS

    Simultaneous ingestion of ferrous sulfate and thyroxine causes a variable reduction in thyroxine efficacy that is clinically significant in some patients. The interaction is probably caused by the binding of iron to thyroxine.

    Links

  • Publisher Full Text

    • Grapherence [↓28]

    Authors+Show Affiliations

    Campbell NR
    ,

    Department of Medicine, Faculty of Medicine, University of Calgary, Alberta, Canada.

    Hasinoff BB
    ,
    Stalts H
    ,
    Rao B
    ,
    Wong NC

    Source

    Annals of internal medicine 117:12 1992 Dec 15 pg 1010-3

    MeSH

    Adult
    Aged
    Female
    Ferrous Compounds
    Humans
    Hypothyroidism
    Male
    Middle Aged
    Patient Compliance
    Spectrophotometry
    Thyrotropin
    Thyroxine

    Pub Type(s)

    Clinical Trial
    Journal Article
    Research Support, Non-U.S. Gov't

    Language

    eng

    PubMed ID

    1443969

    Citation

    * When formatting your citation, note that all book, journal, and database titles should be italicized* Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Ferrous sulfate reduces thyroxine efficacy in patients with hypothyroidism. AU - Campbell,N R, AU - Hasinoff,B B, AU - Stalts,H, AU - Rao,B, AU - Wong,N C, PY - 1992/12/15/pubmed PY - 1992/12/15/medline PY - 1992/12/15/entrez SP - 1010 EP - 3 JF - Annals of internal medicine JO - Ann. Intern. Med. VL - 117 IS - 12 N2 - OBJECTIVE: To determine whether simultaneous ingestion of ferrous sulfate and thyroxine reduces the efficacy of thyroid hormone in patients with primary hypothyroidism. DESIGN: Uncontrolled clinical trial. SETTING: Outpatient research clinic of a tertiary care center. PATIENTS: Fourteen patients with established primary hypothyroidism on stable thyroxine replacement. INTERVENTION: All patients were instructed to ingest simultaneously, a 300-mg ferrous sulfate tablet and their usual thyroxine dose every day for 12 weeks. RESULTS: After 12 weeks of ferrous sulfate ingestion with thyroxine, the mean level of serum thyrotropin (thyroid stimulating hormone, TSH) rose from 1.6 +/- 0.4 to 5.4 +/- 2.8 mU/L (P < 0.01), but the free thyroxine index did not change significantly. Subjective evaluation using a clinical score showed that nine patients had an increase in symptoms and signs of hypothyroidism; the mean score for the 14 patients changed from 0 to 1.3 +/- 0.4 (P = 0.011). When iron and thyroxine were mixed together in vitro, a poorly soluble purple complex appeared that indicated the binding of iron to thyroxine. CONCLUSIONS: Simultaneous ingestion of ferrous sulfate and thyroxine causes a variable reduction in thyroxine efficacy that is clinically significant in some patients. The interaction is probably caused by the binding of iron to thyroxine. SN - 0003-4819 UR - https://www.unboundmedicine.com/medline/citation/1443969/full_citation L2 - https://www.annals.org/article.aspx?volume=117&amp;issue=12&amp;page=1010 DB - PRIME DP - Unbound Medicine ER -